Thalassemia, or thalassemia, is a recessive genetic disease, divided into alpha and beta types, or possibly a combination of alpha and beta types, subdivided into light (i.e., stationary), medium, and heavy. Both parents may inherit from their offspring, and depending on the specific condition of both parents, there may be several inheritance probabilities as follows: 1. One parent is a patient or a gene carrier of thalassemia: the chance of the fetus becoming a gene carrier of thalassemia is 1/2, and the chance of being completely normal is 1/2, and the gene carrier often has no obvious symptoms and often does not develop the disease; 2. Both parents are homozygous for thalassemia or a gene carrier: there is a 1/4 chance The prognosis and survival of children with β-types can be improved and prolonged after active treatment. α-types may be aborted or stillborn at about 30-40 weeks, or die within half an hour after delivery. In general, the fetus may be alpha, beta or a combination of alpha and beta, and is mostly an asymptomatic carrier, and often does not need treatment. However, if one of the husband and wife is a combined alpha and beta carrier, the risk of having a child with one of the other types may increase, and the risk of having a child with severe disease or intermediate type may increase. The above-mentioned genetic rules are not invariable, so it is recommended that couples actively consult and improve their diagnosis before preparing for pregnancy. Generally, couples should consult with the obstetrics and gynecology department of their local maternal and child health center or regular hospital before preparing for pregnancy, and genetic and hematological tests should be performed in early and mid-pregnancy to try to diagnose and terminate the pregnancy for early heavy fetuses to avoid the birth of fetal edema syndrome and heavy fetuses.